Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADB116 in Healthy Chinese Adults
NCT07729839Phase 1Recruiting
- Sponsor
- Aidea Pharma
- Start
- May 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ADB116 (6 cohorts), sponsored by Aidea Pharma. Primary endpoints: Treatment-emergent Adverse Events at 8 days, Maximum Observed Plasma Concentration at 8 days and 9 more. Started May 2026; status: recruiting.
02
Drugs
ADB116
Beyond the preview
Go deeper on NCT07729839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07729839.